ONCOLYTICS BIOTECH INCONCY

ONCOLYTICS BIOTECH INC Segments Disclosure

10-KFiled Mar 30, 20261 min read
Segment Information
We manage our operations as a single reportable and operating segment for the purposes of assessing performance and making operating decisions. Our chief operating decision maker (“CODM”) is made up of our Chief Executive Officer and Chief Financial Officer. The CODM assesses performance and manages and allocates resources on a total company basis. Further, the CODM reviews and utilizes functional expenses at the consolidated level to manage our operations. The measure of segment assets is reported on the consolidated balance sheets as total assets.
The following table provides information about our single segment:

Year Ended December 31,
20252024
Operating Expenses:
   Significant components of research and development (R&D) expenses:
      Clinical trial expenses$1,845 $4,050 
      Manufacturing and related process development expenses4,353 6,018 
      Personnel-related expenses7,001 5,218 
   Significant components of general and administrative (G&A) expenses:
      Public company-related expenses10,238 5,633 
      Personnel-related expenses3,861 3,407 
      Intellectual property expenses584 315 
   All other R&D and G&A expenses843 901 
Total operating expenses28,725 25,542 
Loss from operations(28,725)(25,542)
Total other income, net45 2,843 
Income tax expense(79)(95)
Net loss$(28,759)$(22,794)

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesLeasesCommitmentsNew Standards